To be distributed to ALL, who do NOT want to be "vaccinated"

All vaccines will no longer be justified after 10/20/2021: Information Reviewed. The European Union has approved 5 therapies (https://ec.europa.eu/commission/presscorner/detail/fr/ip_21_3299 ) that will be available in all Member State hospitals for the treatment of covid. These therapies are approved by decree of the European Council (European Parliament) and will be operational from 1/10, therefore they will be gradually distributed around 20/10. The vaccines have been approved on a "provisional trial" basis. However, since there is a prescription requirement for these 5 new drugs by decree, the use of the vaccine will be discontinued. Therefore, we understand why all the states said "between September it is necessary that ...". They already knew everything. You have to be patient. Do not accept blackmail. Be patient. Now that ivermectin is re-approved, there is no need for a vaccine. Excellent news. The Pasteur Institute recognizes the efficacy of ivermectin. A single dose could wipe out all SARS covid-19 genetic material in some people. Good read and share.

 Good news: Ivermectin is now scientifically recognized by researchers at the Pasteur Institute in France as an effective drug, in prophylaxis and treatment of covid-19. The results of their studies were published July 12, 2021, in the journal EMBO Molecular Medicine. An analysis of the results of other research published in the American Journal of Therapeutics strongly urges overriding health authority guidelines and including ivermectin as a standard of care. Macron's government knew about this ...

 Stay healthy and feel free to cheer people who don't want to get vaccinated

 https://www.lettre-docteur-rueff.fr/dr-rueff-biographie/  

 https://www.lettre-docteur-rueff.fr/dr-rueff-biographie/   

----------------------------------

https://ec.europa.eu/commission/presscorner/detail/fr/ip_21_3299  

Press Release June 29, 2021 Brussels

Treatment strategy for COVID-19: Commission identifies five promising treatment candidates

The EU strategy for COVID-19 treatments is now showing early results, with the announcement of an initial portfolio of five treatments that could soon be available to treat patients across the EU. Four of these treatments are monoclonal antibodies under ongoing review by the European Medicines Agency. The fifth is an immunosuppressant with an approval that could be extended to treat patients with COVID-19.

Stella Kyriakides, Commissioner for Health and Food Safety, said, "Today we are taking the first step towards creating a broad portfolio of treatment options for COVID-19. Although vaccination is accelerating, the virus will not go away, and patients need safe and effective treatments to reduce the pressure of COVID-19. Our goal is clear: to identify more breakthrough candidates in development and approve at least three new therapies by the end of the year. This is the European Health Union.

The five products are at an advanced stage of development and have a good chance of being among the three new treatments for COVID-19 that will be approved by October 2021 - the target set in the strategy - provided the final data demonstrate their safety, quality and efficacy. The products are as follows:

A new COVID-19 indication for existing drugs:

Eli Lilly's immunosuppressant baricitinib (a drug that reduces immune system activity): an application to expand approval to include the COVID-19 indication is under review;

Newly developed monoclonal antibodies under continuous evaluation - a regulatory tool to expedite the evaluation of a promising drug in a public health emergency:

Eli Lilly's combination of bamlanivimab and etesevimab: continuous evaluation;

Regeneron Pharmaceuticals, Inc. and F. Hoffman-La Roche, Ltd's combination of casirivimab and imdevimab: ongoing evaluation;

Celltrion's regdanvimab: ongoing evaluation;

Sotrovimab from GlaxoSmithKline and Vir Biotechnology, Inc: ongoing evaluation.

Next steps.

The Commission will develop a portfolio of at least 10 potential treatments for COVID-19 by October, building on the work of the recently established COVID-19 Expert Panel. The selection process will be objective and science-based, with selection criteria agreed with Member States. Because different types of products are needed for different patient populations and different stages and severities of the disease, the expert panel will identify product categories and select the most promising treatment candidates for each category based on scientific criteria.

The portfolio will help ensure that at least three new therapies are approved by October and possibly two more by the end of the year. The European Medicines Agency will conduct further ongoing assessments of promising treatments based on research and development results through the end of 2021.

The Commission recently entered into a joint procurement agreement for the acquisition of monoclonal antibodies (casirivimab and imdevimab) and may initiate additional procedures by the end of the year.

The first industry event for the treatments will be held on July 12-13 to ensure that sufficient quantities of the treatments are produced as soon as possible after their approval.

Background

The EU strategy for COVID-19 therapies aims to build a broad portfolio of COVID-19 therapies, with the goal of developing three new therapies by October 2021 and potentially two more by the end of the year. It encompasses the entire drug lifecycle, from research, development, selection of promising candidates, rapid approval, manufacturing and delivery to end use. 

The strategy is part of strengthening a European Health Union based on a coordinated EU approach to better protect the health of our citizens, with the aim of enabling the EU and its Member States to better prevent and respond to future pandemics and improve the resilience of European health systems.

The strategy, which focuses on treating COVID-19 patients, builds on the EU's successful vaccine strategy, under which safe and effective vaccines against COVID-19 have been approved for use in the EU to prevent transmission of the disease and reduce hospitalizations and deaths from the disease.

For more information

Questions and answers: treatment strategy for COVID-19 - list of 5 possible treatments.

The European Commission's response to coronavirus: treatments.

EU treatment strategy

European Medicines Agency - Treatments for COVID-19.

PDF download at: 

https://ec.europa.eu/commission/presscorner/api/files/document/print/fr/ip_21_3299/IP_21_3299_FR.pdf

 

Comments

Popular posts from this blog

Who knows the Son, knows the Father

DMSO and MMS inactivate Corona Virus

A Test (Teaching) in Humility